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Purpose: To identify predictors for prolonged survival free from salvage whole brain
radiation therapy (WBRT) in patients with brain metastases treated with stereotactic
radiosurgery (SRS) as their initial radiotherapy approach.
Materials and methods: Patients with brain metastases treated with SRS from 2001
to 2013 at our institution were identified. SRS without WBRT was typically offered
to patients with 1–4 brain metastases, Karnofsky performance status 70, and life
expectancy 3months. Three hundred and eight patients met inclusion criteria for
analysis. Medical records were reviewed for patient, disease, and treatment informa-
tion. Two comparison groups were identified: those with 1-year WBRT-free survival
(N=104), and those who died or required salvage WBRT within 3months of SRS
(N=56). Differences between these groups were assessed by univariate and multivariate
analyses.
Results: Median survival for all patients was 11months. Among patients with 1-year
WBRT-free survival, median survival was 33months (12–107months) with only 21%
requiring salvage WBRT. Factors significantly associated with prolonged WBRT-free sur-
vival on univariate analysis (p<0.05) included younger age, asymptomatic presentation,
RTOG RPA class I, fewer brain metastases, surgical resection, breast primary, new
or controlled primary, absence of extracranial metastatic disease, and oligometastatic
disease burden (5 metastatic lesions). After controlling for covariates, asymptomatic
presentation, breast primary, single brain metastasis, absence of extracranial metastases,
and oligometastatic disease burden remained independent predictors for favorable
WBRT-free survival.
Conclusion: A subset of patients with brain metastases can achieve long-term survival
after upfront SRS without the need for salvage WBRT. Predictors identified in this study
can help select patients that might benefit most from a treatment strategy of SRS
alone.
Keywords: brain metastases, radiotherapy, gamma knife, radiosurgery, prognosis, survival analysis
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Introduction
Brain metastases affect approximately one-third of all cancer
patients (1). With recent improvements in life-prolonging sys-
temic therapies, the incidence of brainmetastases is increasing (2).
Although the estimatedmedian survival for all patients with brain
metastases is only 4–6months, there is substantial variability in
prognosis and a subset of patients enjoy survival timeswell beyond
1 year (3, 4).
The appropriate upfront radiotherapy approach for newly diag-
nosed brain metastases is currently controversial with options
that include whole brain radiation therapy (WBRT), stereotactic
radiosurgery (SRS), or both (5–9). Given the potential late neu-
rocognitive effects associated withWBRT, it would be particularly
attractive to avoid it in patients with longer life expectancies
(10–13).
Approximately 40–60% of patients with brain metastases
treated with upfront SRS alone experience regional failures, some
of whom requireWBRT for salvage (5–7). Several tools have been
developed to estimate survival; however, there are no available
methods that predict which patients are likely to achieve long-
term survival without the need for salvageWBRT (3, 4, 14, 15). It is
this group of patients that would have the greatest benefit from an
initial approach of SRS alone. The aim of this study is to identify
patient, disease, and treatment variables that are associated with
prolonged survival free from salvage WBRT.
Materials and Methods
In compliance with institutional review board approval, the
records of patients with brain metastases treated with SRS at
our institution between 2001 and 2013 were reviewed. Patients
who received prior or concurrent WBRT were excluded from this
analysis. Patients who underwent surgical resection followed by
SRS to the resection bed were included. The rates of local failure,
distant CNS failure, salvage treatments, and overall survival were
evaluated. Among eligible patients (N= 308), two groups with the
most divergent outcomes were selected for comparison. The first
group was defined as patients who survived and did not require
salvage WBRT for at least 1 year following SRS (N= 104). The
second group consisted of patients with poor outcomes, which
was defined as patients who either died or required salvageWBRT
within 3months of SRS (N = 56). Patient, disease, and treatment
variables were compared between these two groups.
Steriotactic Radiosurgery Procedure
Patients selected for SRS alone at our institution had one to four
brain metastases, Karnofsky performance status (KPS) 70, and
life expectancy 3months. Occasionally, patients were found to
have additional occult metastases at the time of SRS and >4
lesions were treated with SRS alone. SRS was performed using a
Leksell Gamma Knife Model C (Elekta, Inc., Stockholm, Sweden).
Target lesions were identified using high-resolution magnetic
resonance imaging (MRI) with intravenous gadolinium contrast.
The target volume included the contrast-enhancing lesion with
a 1–2mm margin. Dose was prescribed based on tumor size
according to Radiation Oncology Therapy Group (RTOG) study
90–05 (16). The median dose to the tumor margin was 20Gy
(range 14–22) generally prescribed to the 50% isodose line. Lesser
margins and/or lower doses were used when tumors were near the
brainstem or other sensitive structures.
Outcomes Assessment
Patients were seen in follow-up approximately 1month after their
SRS procedure and every 3months following their initial post-
procedure visit. MRIs were obtained at each scheduled follow-up
visit. Local failurewas defined as an enlarging, contrast-enhancing
lesion on follow-up MRI at the site of SRS treatment. MR spec-
troscopy, MR perfusion analysis, and/or biopsy were performed
when necrosis was suspected. Distant CNS failure was defined as
a new contrast-enhancing lesion outside of the SRS treatment vol-
ume. Salvage WBRT was recommended for patients with distant
CNS failure who had >4 new lesions, KPS <70, or predicted life
expectance of<3months.
Patient, Disease, and Treatment Characteristics
Patient, disease, and treatment data were collected by reviewing
medical records. Patient data included age, gender, race, smoking
status, cancer diagnosis, and histology. Disease variables included
presence of neurological symptoms, number and location of brain
metastases, size of the largest brain metastasis, and the presence
and status of extracranial metastatic disease. Controlled systemic
disease was defined as stable or responding disease onmost recent
imaging prior to SRS. Patients who were treated at initial cancer
diagnosis were considered to have stable disease as they have
not had an opportunity for systemic therapy. Oligometastatic
disease was defined as the presence of 5 metastatic lesions
(CNS included), whereas widespread disease was defined as >5
metastatic lesions (17–19). RTOG recursive partitioning analysis
(RPA) classification was also determined for each patient (3).
Treatment variables included surgical resection and SRS prescrip-
tion dose.
Statistical Analyses
Actuarial local and distant CNS failures and overall survival were
calculated using the Kaplan–Meier method. Age distribution,
number of brain metastases, and size of brain metastases were
evaluated by two-tailed t-tests withWelch’s correction. Chi-square
or Fisher’s Exact Tests were used to compare groups based on
gender, race, smoking status, neurological symptoms, RPA class,
prior surgical resection, location of brain metastases, primary
histology, primary disease status, and extracranial disease status.
Based on the independent variables that were significantly associ-
atedwith 1-yearWBRT-free survival on univariate analysis, amul-
tivariate binary logistic regression analysis was performed. Con-
tinuous variables were converted to binary variables. RPA class
was excluded from the multivariate analysis because of collinear-
ity with multiple independent variables (i.e., age and disease
burden/control). A p-value of <0.05 was considered statistically
significant.
Results
Three hundred and eight patients were treated with SRS alone
and fit inclusion criteria for analysis. The median overall survival
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was 11months. The median WBRT-free survival was 8.5months
(range 0.8–107.3months) with 30% ultimately requiring salvage
WBRT. One hundred and four patients (34%) survived beyond
1 year without the need for salvageWBRT, while 56 patients (18%)
either died or required WBRT within 3months. Figure 1 shows
the survival curve for the entire group of 308 patients treated
with SRS alone and the survival curve for the 104 patients that
form the subgroup with1 yearWBRT-free survival. Themedian
overall survival in the group of patients with 1 year WBRT-
free survival was 33months (range 12–107.3months) with 10%
surviving longer than 5 years. Local failures occurred in 24% with
an actuarial local control of 90.9% at 1 year and 82.2% at 2 years
(Figure 2). Distant CNS failures occurred in 49% with 1 and
2 year actuarial rates of 17.8 and 46.4%, respectively. The median
time to first intracranial salvage treatment was 19months. Salvage
treatments consisted of surgical resection in 7%, SRS in 42%, and
WBRT in 21%.
Table 1 shows the patient, disease, and treatment characteris-
tics of patients with 1 year WBRT-free survival and those with
3months WBRT-free survival. Those with prolonged WBRT-
free survival were significantly younger (p= 0.008), but were oth-
erwise similar in regards to gender and race. Patients with favor-
ableWBRT-free survival were alsomore likely to be asymptomatic
at presentation (p= 0.029) and belong to RPA class I (p< 0.001).
The patients who died or required WBRT within 3months of
SRS had more brain lesions treated at the time of initial SRS
(p< 0.001). The mean size of the largest brain metastasis was
not different between the two groups, but the patients with pro-
longed WBRT-free survival were more likely to have their largest
brain metastasis surgically resected prior to SRS (p= 0.006). The
comparison groups had similar SRS doses prescribed for the
patients’ largest metastases. The majority of patients in both
FIGURE 1 | (A) Survival curve for all patients (N= 308). (B) Survival curve for
1 year WBRT-free survivors (N= 104) (WBRT, whole brain radiation therapy).
groups had lung cancer primaries, but the prolonged WBRT-free
survival group had a larger proportion of breast cancer patients
(p= 0.048), while the group with poor outcomes had a larger
proportion of melanoma patients (p= 0.039). Patients with pro-
longed WBRT-free survival were more likely to have their cancer
diagnosis coincident with the diagnosis of brain metastases or
have a pre-existing cancer diagnosis with a controlled primary
(p= 0.007). Extracranial metastatic disease was more common in
the patients who died or requiredWBRT within 3months of their
SRS procedure (p< 0.001). Total disease burdenwas characterized
as oligometastatic in 76.9% of patients with 1 year WBRT-free
survival, while 60.7% of patients with 3months WBRT-free
survival had widespread disease (p< 0.001).
The variables significantly associated with favorable WBRT-
free survival identified by the univariate analyses were further
evaluated with a multivariate binary logistic regression analysis
(Table 2). When controlling for covariates, independent predic-
tors of favorable WBRT-free survival were asymptomatic pre-
sentation, breast primary, single brain metastasis, absence of
extracranial metastases, and oligometastatic disease burden.
Discussion
Patients with brain metastases represent a very heterogeneous
population. The optimal treatment for these patients remains an
area of controversy. Survival well beyond 1 year is observed in a
notable subset. For these patients, aggressive treatment to control
their CNS disease is warranted.
Stereotactic radiosurgery alone has been adopted by many to
treat patients with limited brain metastases and expected survival
FIGURE 2 | CNS disease outcomes for patients with1 year
WBRT-free survival. (A) Local progression. (B) Distant CNS progression
(CNS, central nervous system; WBRT, whole brain radiation therapy).
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TABLE 1 | Patient, disease, and treatment variables stratified by WBRT-free
survival group.
1 year
WBRT-free
survivors
N= 104
3months
WBRT-free
survivors
N= 56
p-Value
Age, mean [range] 60 year [30, 83] 66 year [32, 89] 0.008
Gender, N (%)
Male 43 (41%) 31 (55%) 0.063
Female 61 (59%) 25 (45%)
Race, N (%)
Caucasian 95 (91.3%) 48 (85.7%) 0.223
African American 1 (1.0%) 4 (7.1%)
Hispanic 6 (5.8%) 2 (3.6%)
Other 2 (1.9%) 2 (3.6%)
Smoking status, N (%)
Active 23 (22.1%) 14 (25.0%) 0.263
Former 42 (40.4%) 22 (39.3%)
Never 21 (20.2%) 16 (28.6%)
Unknown 18 (17.3%) 4 (7.1%)
Neurological symptoms, N (%)
Yes 72 (69.2%) 44 (78.6%) 0.029
No 29 (27.9%) 7 (12.5%)
Unknown 3 (2.9%) 5 (8.9%)
RTOG RPA, N (%)
Class I 40 (38.5%) 6 (10.7%) <0.001
Class II 61 (58.7%) 48 (85.7%)
Unknown 3 (2.9%) 2 (3.6%)
Number of brain mets
[mean (range)]
2 [1–9] 4 [1–13] <0.001
CNS disease burden, N (%)
Single met 64 (61.5%) 16 (28.6%) <0.001
Multiple mets 40 (38.5%) 40 (71.4%)
Size of largest met [mean
diameter (range)]
2 cm [0.3–5.4] 2 cm [0.6–3.8] 0.762
Minimum dose [mean (range)] 19Gy [14, 22] 18Gy [14, 22] 0.149
Prior surgical resection, N (%) 30 (28.8%) 6 (10.7%) 0.006
Primary Histology, N (%)
NSCLC 60 (57.7%) 29 (51.7%) 0.508
Breast 16 (15.4%) 3 (5.4%) 0.048
Melanoma 5 (4.8%) 8 (14.3%) 0.039
Other 22 (21.1%) 16 (28.6%) 0.158
Primary Status, N (%)
New/controlled 86 (82.6%) 35 (62.5%) 0.007
Progressive 9 (8.7%) 13 (23.2%)
Unknown 9 (8.7%) 6 (10.7%)
Extracranial mets, N (%)
Yes 28 (26.2%) 37 (66.1%) <0.001
No 67 (64.4%) 11 (19.6%)
Unknown 9 (8.7%) 6 (10.7%)
Total disease burden, N (%)
Oligometastatic 80 (76.9%) 17 (30.4%) <0.001
Widespread 14 (14.4%) 34 (60.7%)
Unknown 9 (7.7%) 5 (8.9%)
Bold font indicates p<0.05.
WBRT, whole brain radiation therapy; RTOG, Radiation Therapy Oncology Group; RPA,
recursive partitioning analysis; met, metastasis; CNS, central nervous system; NSCLC,
non-small cell lung cancer.
3months. Using this approach, distant CNS failures in approx-
imately 50% are expected (5–7). To improve CNS control, oth-
ers have adopted a combined approach of SRS and WBRT (8,
9). For the group of patients with potential for long-term sur-
vival, late treatment-related neurocognitive morbidity of WBRT
must be considered (10–13). Three randomized phase III trials
have evaluated SRS alone compared with WBRT and SRS (5–7).
TABLE 2 |Multivariate analysis comparing1 year WBRT-free survivors vs.
3months WBRT-free survivors.
Odds Ratio for 1 year
WBRT-free survivala
p-Value
Age
<65 years vs. 65 years 1.81 [0.67, 4.88] 0.241
Primary histology
Breast vs. other 7.84 [1.34, 45.93] 0.022
Melanoma vs. other 0.59 [0.93, 3.77] 0.579
Primary disease status
New/controlled vs. progressive 1.10 [0.36, 3.32] 0.871
Neurological symptoms
Present vs. absent 0.19 [0.06–0.63] 0.007
Resected brain met
Yes vs. no 2.93 [0.76–11.38] 0.120
Number of brain mets
Single vs. multiple 3.07 [1.06–8.4] 0.038
Extracranial mets
Present vs. absent 0.24 [0.08–0.70] 0.009
Disease burden
Oligometastatic vs. widespread 6.32 [2.00–19.99] 0.002
Bold font indicates p< 0.05.
aRelative to 3months WBRT-free survival.
WBRT, whole brain radiation therapy; met, metastasis.
WBRT was shown to decrease the risk of distant CNS failure
by 15–22%. However, a meta-analysis of these trials showed no
survival advantage with the addition of WBRT to SRS; rather, in
patients 50 years of age, WBRT was associated with increased
mortality (20). Additionally, given the potential acute and late side
effects of adding WBRT, it would be ideal to identify a patient
cohort that is likely to achieve prolonged survival and yet unlikely
to gain benefit fromWBRT.
Several nomograms have been developed to predict survival
in patients with brain metastases. Gaspar et al. performed a
RPA using a database from RTOG trials with 1,200 patients and
identified three prognostic groups (3). The median survivals for
RPA class I (KPS 70, controlled primary, age <65 years, brain
metastasis only), class II (not meeting criteria for classes I or III),
and class III (KPS <70) were 7.1, 4.2, and 2.3months, respec-
tively. A more recent analysis seeking to better stratify patients
is the disease-specific graded prognostic assessment (DS-GPA)
(4). The RPA and DS-GPA scoring systems were developed based
on patients who were primarily treated with WBRT and not with
SRS alone. Two other groups have developed predictive models
using large databases of patients treated solely with SRS (14, 15).
Although the aforementioned prognostic systems were based on
large numbers of patients and have been validated to estimate
overall survival, they do not predict the likelihood of regional
failure or the need for salvage WBRT.
Our study aimed to identify patient, disease, and treatment
variables that might predict for patients who are likely to not
only have prolonged survival, but also are unlikely to require
salvage WBRT. We intentionally selected two groups of patients
with the contrasting outcomes after SRS alone. Patients who lived
beyond 1 year without WBRT had a median survival of almost
3 years, and only 21% eventually required salvage WBRT. It is
important to note that the rate of salvage WBRT is dependent
on the criteria used to offer salvage WBRT as compared with
other salvage options such as repeat SRS. In our cohort, repeat
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SRSwas offered only for patientswith limited (4) newmetastases
and life-expectancy of at least 3months, the same criteria as pri-
mary treatment. Patients not meeting these criteria were offered
WBRT for salvage. Although some have advocated SRS alone for
>4 and even>10 lesions, these patients suffer from a high rate of
distant CNS failure (21, 22). A median time to distant CNS failure
of only 3months was seen in our experience treating patients with
>10 lesions (23). We, therefore, have not offered routine salvage
SRS for patients with>4 metastases.
In this study, predictors of 1 year WBRT-free survival on
univariate analyses included younger age, RPA class I, breast
primary, new or controlled primary, asymptomatic presentation,
surgical resection of a brain metastasis, fewer brain metastases,
absence of extracranial metastases, and oligometastatic disease.
On multivariate analysis, asymptomatic presentation, breast pri-
mary, single brain metastasis, absence of extracranial metas-
tases, and oligometastatic disease burden remained significantly
associated with prolonged WBRT-free survival. Kondziolka et al.
performed an analysis of 44 patients that survived longer than
4 years after SRS and compared them to patients that died within
3months (24). They showed that patients with prolonged survival
were significantly more likely to have fewer brain lesions, higher
initial performance status, and less extracranial disease. In this
study, however, 38 of the 44 patients received prior or concurrent
WBRT. Kress et al. evaluated a cohort of non-small cell lung
cancer patients treated with SRS alone to a single brain metastasis
and showed that progression of systemic disease correlated with
distant CNS failure (25). Ayala-Peacock et al. performed an analy-
sis of 464 patients treatedwith SRS alone atWake ForestUniversity
and evaluated variables predicting for distant CNS failure and
need for salvage therapies (26). Histology (melanoma and HER2
negative breast cancer), progressive systemic disease, number of
metastases (4–13 vs. 1–3), and occult metastases at time of SRS
were found to be predictive of early time to distant CNS failure.
Our data are consistent with these studies, showing that active
disease burden, both in the brain and systemically, is the most
influential predictor of WBRT-free survival.
The concept of oligometastatic disease was initially described
by Hellman and Weichselbaum in 1995 (17). It is defined as a
state between local-regional disease and wide-spread metastatic
disease where metastases are few in number. In recent years,
the oligometastatic disease state has gained much interest, as
these patients have a more favorable prognosis compared to other
stage IV patients (18, 19). In our study, oligometastatic disease
was strongly associated with longer WBRT-free survival in both
univariate and multivariate analyses. In the favorable group, over
three quarters of the patients had oligometastatic disease com-
pared to only one-third in the poor prognosis group.
Another interesting, but not surprising, finding fromour analy-
sis is the relationship between primary tumor type andWBRT-free
survival. Multiple prior reports have demonstrated that compared
to other histologies, overall survival outcomes are relatively better
in patients with breast cancer (4, 27). Furthermore, recent data
suggest that molecular subtypes of breast cancer are important
in predicting survival, as well as CNS control after SRS alone
(28, 29). Specifically, patients with HER2/neu over-expressing
breast cancer with brain metastases have a lower risk of death and
intracranial recurrence after treatment compared to patients with
other breast cancer subtypes.
The interpretation of our results is limited by the retrospec-
tive nature and non-randomized study design, which introduces
multiple well-described biases in data collection and analysis
(30). Despite these potential shortcomings, using our institution’s
guidelines for patient selection (4 CNSmetastases and expected
survival >3months), 82% survived >3months without requir-
ing salvage WBRT and 34% survived >1 year without requiring
WBRT. The results from our multivariate analysis suggest that
patients who have oligometastic disease, controlled systemic dis-
ease, a breast primary and/or asymptomatic brain disease are
expected to have favorable outcomes after SRS alone. Similarly,
patients with widespread disease might be more optimally man-
aged with the upfront incorporation of WBRT. Although a larger,
prospective cohort of patients needs to be studied to confirm
these findings, the identified predictive variables can be used to
compliment and improve multi-disciplinary decision-making.
Conclusion
Our results identify several variables related to intracranial and
systemic disease burden that can help select patients that are likely
to achieve prolonged survival and less likely to require salvage
WBRT. This group of patients is ideally suited for SRS alone as
their upfront radiotherapy approach. Further validation of these
variables in a prospective cohort of patients is needed.
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